Jim Cramer Notes Becton Dickinson Stock Recently “Finished in the Black”

Becton, Dickinson and Company (NYSE:BDX) is one of the stocks on Jim Cramer’s radar. Cramer mentioned the stock in light of its recent deal with Waters, as he commented:

“Any one of the majors will be thrilled to snap some of these brands because there’s very little organic growth in the industry. The only way you can have any growth is buy it. Alright, now, how about this merger today between Becton Dickinson, this was the Life Science and Diagnostic division, which had been shopped extensively, and Waters, a really strong company, we’ve had them on, a dominant player in exactly those fields. The deal was done in a very confusing Reverse Morris Trust way, which is one of those tax-saving situations that the Street almost always hates, but the CEOs think it’s so smart, and they hate it because they aren’t easy.

They’re, they’re not clean…. Becton Dickinson’s getting a 39.2% stake in the newly combined Waters, yet after selling off this morning, the stock actually finished in the black. It seemed like a great deal to me, especially because the company got $4 billion in cash and assumed $4 billion in debt. Really good deal for Becton Dickinson. But again, it’s hard to get your head around. So it didn’t bring out many buyers, at least not today.  Believe me, that will change…”

A surgeon performing a procedure in an operating room using a medical device supplied by the company.

Becton, Dickinson (NYSE:BDX) manufactures medical devices, supplies, and diagnostic products used across healthcare, research, and clinical settings. The company’s products support drug delivery, lab testing, surgical procedures, and patient monitoring.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.